The Planning and Evaluation Core will oversee project selection and monitoring as well as oversee the overall partnership progress toward objectives and priorities. The objectives are 1. To create the structural framework through which collaborative programs in cancer research, education and training can be established, maintained and institutionalized between CDU and JCCC; 2. To ensure that quality cancer research is being produced and that project investigators are successfully moving forward with their research;and 3. To evaluate process, outcomes, and impact of all partnership core, program, or project activities. Planning and evaluation will be constantly ongoing, and the outcomes of those processes will constitute the basis for initiating and terminating the investment of resources into developmental projects, programs, resources, and recruitments. The Planning and Evaluation Core comprises two committees: 1) an Intemal Advisory Committee (IAC), which will focus on program planning and research and investigator progress and 2) a Program Steering Committee (PSC), which will assess and evaluate partnership activities within the Development Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143931-04
Application #
8381215
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$42,890
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Type
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11
Wu, Yanyuan; Tran, Trinh; Dwabe, Sami et al. (2017) A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 163:449-460
Maxwell, Annette E; Young, Sandra; Moe, Emily et al. (2017) Understanding Factors that Influence Health Care Utilization Among Mixtec and Zapotec Women in a Farmworker Community in California. J Community Health :
Dong, Yunzhou; Wu, Yong; Cui, Mei-Zhen et al. (2017) Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21. Mediators Inflamm 2017:2754756
Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
McGhee, Eva; Harper, Hill; Ume, Adaku et al. (2017) Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President's Cancer Panel Report on HPV Vaccinations. J Vaccines Vaccin 8:

Showing the most recent 10 out of 79 publications